Allogene Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.105
- Today's High:
- $4.278
- Open Price:
- $4.14
- 52W Low:
- $5.41
- 52W High:
- $17.49
- Prev. Close:
- $4.11
- Volume:
- 908807
Company Statistics
- Market Cap.:
- $861.20 million
- Book Value:
- 4.61
- Revenue TTM:
- $243000
- Operating Margin TTM:
- -138044.86%
- Gross Profit TTM:
- $243000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.6%
- Return on Equity TTM:
- -42.04%
Company Profile
Allogene Therapeutics Inc had its IPO on 2018-10-11 under the ticker symbol ALLO.
The company operates in the Healthcare sector and Biotechnology industry. Allogene Therapeutics Inc has a staff strength of 359 employees.
Stock update
Shares of Allogene Therapeutics Inc opened at $4.14 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.11 - $4.28, and closed at $4.19.
This is a +1.95% increase from the previous day's closing price.
A total volume of 908,807 shares were traded at the close of the day’s session.
In the last one week, shares of Allogene Therapeutics Inc have increased by +3.46%.
Allogene Therapeutics Inc's Key Ratios
Allogene Therapeutics Inc has a market cap of $861.20 million, indicating a price to book ratio of 1.5084 and a price to sales ratio of 4133.631.
In the last 12-months Allogene Therapeutics Inc’s revenue was $243000 with a gross profit of $243000 and an EBITDA of $-321153984. The EBITDA ratio measures Allogene Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Allogene Therapeutics Inc’s operating margin was -138044.86% while its return on assets stood at -22.6% with a return of equity of -42.04%.
In Q3, Allogene Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 7.8%.
Allogene Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allogene Therapeutics Inc’s profitability.
Allogene Therapeutics Inc stock is trading at a EV to sales ratio of 2674.7514 and a EV to EBITDA ratio of -2.2207. Its price to sales ratio in the trailing 12-months stood at 4133.631.
Allogene Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $887.57 million
- Total Liabilities
- $48.87 million
- Operating Cash Flow
- $24.91 million
- Capital Expenditure
- $223000
- Dividend Payout Ratio
- 0%
Allogene Therapeutics Inc ended 2025 with $887.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $887.57 million while shareholder equity stood at $739.96 million.
Allogene Therapeutics Inc ended 2025 with $0 in deferred long-term liabilities, $48.87 million in other current liabilities, 144000.00 in common stock, $-1141133000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $74.36 million and cash and short-term investments were $552.23 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Allogene Therapeutics Inc’s total current assets stands at $569.06 million while long-term investments were $99.15 million and short-term investments were $477.87 million. Its net receivables were $9.38 million compared to accounts payable of $11.05 million and inventory worth $0.
In 2025, Allogene Therapeutics Inc's operating cash flow was $24.91 million while its capital expenditure stood at $223000.
Comparatively, Allogene Therapeutics Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $4.19
- 52-Week High
- $17.49
- 52-Week Low
- $5.41
- Analyst Target Price
- $22.69
Allogene Therapeutics Inc stock is currently trading at $4.19 per share. It touched a 52-week high of $17.49 and a 52-week low of $17.49. Analysts tracking the stock have a 12-month average target price of $22.69.
Its 50-day moving average was $4.57 and 200-day moving average was $5.84 The short ratio stood at 22.1 indicating a short percent outstanding of 0%.
Around 2971.8% of the company’s stock are held by insiders while 7903.5% are held by institutions.
Frequently Asked Questions About Allogene Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.